Mankind Pharma reported a 17% year-on-year drop in consolidated net profit to ₹378 crore in Q1 FY26, despite an 11% rise in revenue. The company also declared a ₹5 per share dividend, maintaining its payout strategy amid a subdued quarter.
India’s leading domestic-focused pharma company, Mankind Pharma, announced its financial results for the quarter ending June 30, 2025 (Q1 FY26).
Key highlights include:
-
Net profit: ₹378 crore, down 17% YoY
-
Revenue from operations: ₹2,755 crore, up 11% YoY
-
EBITDA: ₹590 crore, down 8% YoY
-
EBITDA margin: 21.4% vs 25.2% in Q1 FY25
The decline in profitability was attributed to higher employee expenses, increased R&D investments, and raw material costs, according to the company’s earnings statement.
Rajeev Juneja, Vice Chairman and Managing Director, said:
“We are continuing our efforts toward operational excellence while investing strategically in R&D and talent. Our focus remains on long-term value creation and strengthening our therapeutic leadership across chronic and acute segments.”
Dividend Declared
The Board of Directors approved a ₹5 interim dividend per equity share, consistent with the company’s shareholder return policy. The record date for dividend eligibility will be notified soon.
